Dupixent (Dupilumab): Indications and Dosing
Dupixent is FDA-approved for six major indications: atopic dermatitis (≥6 months old), asthma (≥6 years old), chronic rhinosinusitis with nasal polyps (≥12 years old), eosinophilic esophagitis (≥1 year old, ≥15 kg), prurigo nodularis (adults), and COPD (adults), with specific weight-based and age-based dosing regimens for each condition. 1
Atopic Dermatitis
Adults
- Initial dose: 600 mg (two 300 mg injections) subcutaneously
- Maintenance: 300 mg every 2 weeks (Q2W) 1
This represents the first-line systemic agent for moderate-to-severe atopic dermatitis when topical therapies fail, as unanimously favored by guideline workgroup members over all other systemic options including JAK inhibitors 2. Dupilumab has demonstrated excellent safety over 5+ years in clinical practice with significant improvements in quality of life 2.
Pediatric Patients (6 months to 5 years)
- 5 to <15 kg: 200 mg every 4 weeks (Q4W)
- 15 to <30 kg: 300 mg every 4 weeks (Q4W)
- No loading dose required 1
Pediatric Patients (6 to 17 years)
| Body Weight | Loading Dose | Maintenance |
|---|---|---|
| 15 to <30 kg | 600 mg (two 300 mg injections) | 300 mg Q4W |
| 30 to <60 kg | 400 mg (two 200 mg injections) | 200 mg Q2W |
| ≥60 kg | 600 mg (two 300 mg injections) | 300 mg Q2W |
Key point: Dupilumab can be used with or without topical corticosteroids. Reserve topical calcineurin inhibitors for problem areas only (face, neck, intertriginous, genital areas) 1.
Asthma
Adults and Pediatric Patients ≥12 Years
Standard dosing:
- Loading: 400 mg (two 200 mg injections) OR 600 mg (two 300 mg injections)
- Maintenance: 200 mg Q2W OR 300 mg Q2W 1
For oral corticosteroid-dependent asthma OR comorbid moderate-to-severe atopic dermatitis OR comorbid chronic rhinosinusitis with nasal polyps:
- Loading: 600 mg (two 300 mg injections)
- Maintenance: 300 mg Q2W 1
Pediatric Patients (6 to 11 years)
- 15 to <30 kg: 300 mg Q4W (no loading dose)
- ≥30 kg: 200 mg Q2W (no loading dose)
Exception: If comorbid moderate-to-severe atopic dermatitis exists, use the atopic dermatitis dosing table which includes a loading dose 1.
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
For patients ≥12 years:
- 300 mg every 2 weeks (Q2W) 1
- No loading dose specified
Dupilumab is indicated for inadequately controlled CRSwNP as add-on maintenance treatment 1. Real-world data demonstrates sustained effectiveness with meaningful improvements in nasal polyp scores, quality of life (SNOT-22), and olfactory function maintained through 12 months 3, 4.
Important consideration: After 6-12 months of standard Q2W dosing with good disease control, extended interval dosing to Q4W maintains clinical stability without significant deterioration in nasal polyp scores, SNOT-22, or radiologic findings 5. Selected patients may extend further to Q6W-Q12W 5. This applies even in patients with comorbid asthma, where asthma control remains stable during interval extension 6.
Eosinophilic Esophagitis (EoE)
For patients ≥1 year old, weighing ≥15 kg:
| Body Weight | Dosing |
|---|---|
| 15 to <30 kg | 200 mg Q2W |
| 30 to <40 kg | 300 mg Q2W |
| 40 kg or more | 300 mg every week (QW) |
Prurigo Nodularis
Adults only:
- Loading: 600 mg (two 300 mg injections)
- Maintenance: 300 mg Q2W 1
Chronic Obstructive Pulmonary Disease (COPD)
Adults with inadequately controlled COPD and eosinophilic phenotype:
Administration Essentials
Injection Technique
- Subcutaneous injection into thigh or abdomen (avoid 2 inches around navel)
- Upper arm acceptable if caregiver administers
- Rotate injection sites with each dose
- Avoid tender, damaged, bruised, or scarred skin 1
Preparation
- Remove from refrigerator and allow to reach room temperature:
- 45 minutes for 300 mg/2 mL formulation
- 30 minutes for 200 mg/1.14 mL formulation
- Must use within 14 days after removal from refrigerator 1
Missed Doses
- Weekly dosing: Give as soon as possible, restart weekly schedule from that date
- Q2W dosing: If within 7 days of missed dose, give immediately and resume original schedule; if >7 days late, wait until next scheduled dose
- Q4W dosing: If within 7 days, give and resume original schedule; if >7 days late, give dose and start new schedule from that date 1
Critical Safety Considerations
Pre-Treatment
Complete age-appropriate vaccinations before initiating therapy 1. Avoid live vaccines during treatment 1.
Screen and treat helminth infections before starting; if infection occurs during treatment and doesn't respond to anti-helminth therapy, discontinue dupilumab until resolved 1.
Monitoring During Treatment
Ophthalmologic concerns: Conjunctivitis and keratitis occur commonly. Instruct patients to report new or worsening eye symptoms immediately; consider ophthalmologic examination 1.
Eosinophilic conditions: Monitor for vasculitic rash, worsening pulmonary symptoms, or neuropathy, particularly when reducing oral corticosteroids 1.
Arthralgia: New or worsening joint symptoms warrant rheumatologic evaluation and potential discontinuation 1.
Blood eosinophil elevations: Can occur both short-term and long-term in CRSwNP patients; monitor carefully, though levels typically return toward baseline by 12 months 3.
Corticosteroid Tapering
Never abruptly discontinue systemic, topical, or inhaled corticosteroids when starting dupilumab. Taper gradually if appropriate 1.
Common Pitfalls
- Forgetting loading doses: Most indications require loading doses except pediatric asthma (6-11 years), pediatric AD (6 months-5 years), CRSwNP, and COPD
- Wrong formulation for age: Pre-filled pen only for ≥2 years; pre-filled syringe for ≥6 months 1
- Inadequate warm-up time: Injecting cold medication increases injection site reactions
- Premature discontinuation for eye symptoms: Most conjunctivitis cases are manageable without stopping therapy
- Not considering comorbidities: Patients with multiple type 2 inflammatory conditions (asthma + AD, asthma + CRSwNP) benefit from single-agent treatment addressing all conditions 7, 8